Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay

Journal of Virological Methods

Volumn 215-216, Issue , 2015, Pages 56-60

  Hou, Wangheng ^a   Yang, Lisheng ^a   He, Delei ^a   Zheng, Jun ^a   Xu, Longfa ^a   Liu, Jian ^a   Liu, Yajing ^a   Zhao, Huan ^a   Ye, Xiangzhong ^b   Cheng, Tong ^a   Xia, Ningshao ^a  

^a XIAMEN UNIVERSITY   (China)

^b Beijing Wantai Biological Pharmacy Enterprise Co Ltd   (China)

Author keywords

Antibody; Coxsackievirus A16; ELISPOT; Enterovirus; Neutralization

Indexed keywords

COXSACKIE VIRUS A16 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7D10; NEUTRALIZING ANTIBODY; PROTEIN VP1; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS A; COXSACKIE VIRUS A16; COXSACKIE VIRUS INFECTION; CYTOPATHOGENIC EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; HIGH THROUGHPUT SCREENING; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS NEUTRALIZATION; BLOOD; ENTEROVIRUS; EVALUATION STUDY; HUMAN; IMMUNOLOGY; PROCEDURES; SERODIAGNOSIS; TIME;

COXSACKIEVIRUS; ENTEROVIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENTEROVIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEUTRALIZATION TESTS; TIME FACTORS;

EID: 84924287376     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2015.02.010     Document Type: Article

References (26)

1. AbuBakar S., Chee H.Y., Al-Kobaisi M.F., Xiaoshan J., Chua K.B., Lam S.K. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia. Virus Res. 1999, 61:1-9.
2. Andrewes C.H., Elford W.J. Observations on anti-phage sera. I: the percentage law. Br. J. Exp. Pathol. 1933, 14:367-376.
3. Brioen P., Boeye A. Poliovirus neutralization and the percentage law. Brief report. Arch. Virol. 1985, 83:105-111.
4. Cabrerizo M., Tarrago D., Munoz-Almagro C., Del Amo E., Dominguez-Gil M., Eiros J.M., Lopez-Miragaya I., Perez C., Reina J., Otero A., Gonzalez I., Echevarria J.E., Trallero G. Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain. Clin. Microbiol. Infect. 2014, 20:O150-O156.
5. Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., Huang Z. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013, 31:2215-2221.
6. Feder H.M., Bennett N., Modlin J.F. Atypical hand, foot, and mouth disease: a vesiculobullous eruption caused by Coxsackie virus A6. Lancet Infect. Dis. 2014, 14:83-86.
7. Goksugur N., Goksugur S. Images in clinical medicine. Hand, foot, and mouth disease. N. Engl. J. Med. 2010, 362:e49.
8. Huang M.L., Chiang P.S., Luo S.T., Liou G.Y., Lee M.S. Development of a high-throughput assay for measuring serum neutralizing antibody against enterovirus 71. J. Virol. Methods 2010, 165:42-45.
9. Jin J., Ma H., Xu L., An D., Sun S., Huang X., Kong W., Jiang C. Development of a Coxsackievirus A16 neutralization assay based on pseudoviruses for measurement of neutralizing antibody titer in human serum. J. Virol. Methods 2013, 187:362-367.
10. Jin J., Xu L., Guo S.J., Sun S.Y., Zhang S., Zhu C.L., Kong W., Jiang C.L. Safe and objective assay of enterovirus 71 neutralizing antibodies via pseudovirus. Chem. Res. Chin. Univ. 2012, 28:91-95.
11. Li J., Chang J., Liu X., Yang J., Guo H., Wei W., Zhang W., Yu X.F. Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J. Gen. Virol. 2014, 95:1083-1093.
12. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., Zhang Y., Li Y., Mao Q., Wang J., Jiang L., Dong C., Che Y., Huang T., Jiang Z., Xie Z., Wang L., Liao Y., Liang Y., Nong Y., Liu J., Zhao H., Na R., Guo L., Pu J., Yang E., Sun L., Cui P., Shi H., Wang J., Li Q. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 2014, 370:829-837.
13. Li Y.P., Liang Z.L., Xia J.L., Wu J.Y., Wang L., Song L.F., Mao Q.Y., Wen S.Q., Huang R.G., Hu Y.S., Yao X., Miao X., Wu X., Li R.C., Wang J.Z., Yin W.D. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, randomized, double-blind, placebo-controlled Trial. J. Infect. Dis. 2014, 209:46-55.
14. Mao Q., Cheng T., Zhu F., Li J., Wang Y., Li Y., Gao F., Yang L., Yao X., Shao J., Xia N., Liang Z., Wang J. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS ONE 2013, 8:e79599.
15. McMinn P., Stratov I., Nagarajan L., Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin. Infect. Dis. 2001, 32:236-242.
16. Oberste M.S., Maher K., Flemister M.R., Marchetti G., Kilpatrick D.R., Pallansch M.A. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J. Clin. Microbiol. 2000, 38:1170-1174.
17. Pierson T.C., Sanchez M.D., Puffer B.A., Ahmed A.A., Geiss B.J., Valentine L.E., Altamura L.A., Diamond M.S., Doms R.W. A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology 2006, 346:53-65.
18. Qi An W., Guo Su Z., Wen Pan R., Ping Yang B., Chao Zhang Y., Shi L., Li Q. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum. Vaccin. Immunother. 2014, 10:628-639.
19. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 1938, 27:493-497.
20. Shimizu H., Utama A., Yoshii K., Yoshida H., Yoneyama T., Sinniah M., Yusof M.A., Okuno Y., Okabe N., Shih S.R., Chen H.Y., Wang G.R., Kao C.L., Chang K.S., Miyamura T., Hagiwara A. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn. J. Infect. Dis. 1999, 52:12-15.
21. Tagaya I., Takayama R., Hagiwara A. A large-scale epidemic of hand, foot and mouth disease associated with enterovirus 71 infection in Japan in 1978. Jpn. J. Med. Sci. Biol. 1981, 34:191-196.
22. Wu X., Mao Q., Yao X., Chen P., Chen X., Shao J., Gao F., Yu X., Zhu F., Li R., Li W., Liang Z., Wang J., Lu F. Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS ONE 2013, 8:e64116.
23. Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., Cowling B.J., Varma J.K., Farrar J.J., Leung G.M., Yu H. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect. Dis. 2014, 14:308-318.
24. Yang L., He D., Tang M., Li Z., Liu C., Xu L., Chen Y., Du H., Zhao Q., Zhang J., Cheng T., Xia N. Development of an enzyme-linked immunosorbent spot assay to measure serum-neutralizing antibodies against coxsackievirus B3. Clin. Vaccine Immunol. 2014, 21:312-320.
25. Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., Hu Y., Ji T., Song L., Liang Q., Zhang B., Gao Q., Li J., Wang S., Hu Y., Gu S., Zhang J., Yao G., Gu J., Wang X., Zhou Y., Chen C., Zhang M., Cao M., Wang J., Wang H., Wang N. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 2014, 370:818-828.
26. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., Hu Y.M., Wu X., Liu P., Zhu L.Y., Gao F., Jin H., Chen Y.J., Dong Y.Y., Liang Y.C., Shi N.M., Ge H.M., Liu L., Chen S.G., Ai X., Zhang Z.Y., Ji Y.G., Luo F.J., Chen X.Q., Zhang Y., Zhu L.W., Liang Z.L., Shen X.L. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381:2024-2032.